Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001374170-25-000064
Filing Date
2025-07-24
Accepted
2025-07-24 11:22:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4835
  Complete submission text file 0001374170-25-000064.txt   6570
Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Subject) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-40503 | Film No.: 251145344
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address BANKPLASSEN 2 P.O BOX 1179 SENTRUM OSLO Q8 0107
Business Address BANKPLASSEN 2 P.O BOX 1179 SENTRUM OSLO Q8 0107 47-24073120
NORGES BANK (Filed by) CIK: 0001374170 (see all company filings)

EIN.: 000000000 | State of Incorp.: Q8 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A